HealthDay News – Pitavastatin lowers blood total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides in a dose-dependent manner, according to a review recently published in the Cochrane Database of Systematic Reviews.
Stephen P. Adams, from University of British Columbia in Vancouver, Canada, and colleagues conducted a systematic literature review to identify studies quantifying the effects of various doses of pitavastatin on the surrogate markers, including LDL cholesterol, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, in participants with and without cardiovascular disease.
The researchers identified 47 studies (5 randomized controlled trials and 42 before-and-after studies; total 5436 participants) with treatment evaluated for 3 to 12 weeks. Over doses of 1mg to 16mg, log dose-response data showed strong linear dose-related effects on blood total cholesterol, LDL cholesterol, and triglycerides. There was no dose-related effect of pitavastatin on blood HDL cholesterol. However, reductions were seen in LDL cholesterol (33.3 to 54.7%), total cholesterol (23.3 to 39.0%), and triglycerides (13.0 to 28.1%) with pitavastatin 1mg/day to 16mg/day. For every twofold dose increase in pitavastatin, there was a 5.35% decrease in blood LDL cholesterol, a 3.93% decrease in blood total cholesterol, and a 3.76% decrease in blood triglycerides. This effect on LDL cholesterol was greater than for other statins (sixfold more potent than atorvastatin, 1.7-fold more potent than rosuvastatin, 77-fold more potent than fluvastatin, but 3.3-fold less potent than cerivastatin).
“There is a high level of trust around the effects of pitavastatin on total cholesterol, LDL cholesterol, and triglycerides,” the authors write.